

BIOCON GROUP

FACT SHEET

March - 2021

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4'FY 21	Q4'FY 20	Variance %
INCOME			
Generics	578	562	3%
Biosimilars	664	433	53%
Novel Biologics	-	-	-
Research services	659	607	8%
Inter-segment	(61)	(45)	35%
Revenue from operations #	1,839	1,558	18%
Other income	205	63	226%
TOTAL REVENUE	2,044	1,621	26%
EXPENDITURE			
Material & Power costs	644	601	7%
Staff costs	414	354	17%
Research & Development expenses*	127	125	2%
Other expenses	218	159	37%
Manufacturing, staff & other expenses	1,403	1,239	13%
EBITDA	641	382	68%
Interest & Finance charges	34	17	102%
Depreciation & Amortisation	184	152	21%
Share of loss / (profit) in JV / Associate, net	70	-	100%
PBT BEFORE EXCEPTIONAL ITEM	354	213	66%
Exceptional item, Net	13	-	100%
PBT FROM CONTINUING OPERATIONS	366	213	72%
Taxes	60	45	33%
Taxes on exceptional item	10	-	100%
NET PROFIT BEFORE MINORITY INTEREST	297	168	77%
Minority interest	36	36	2%
Minority interest on exceptional item	7	-	100%
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	254	132	92%
LOSS FROM DISCONTINUING OPERATION	-	8	-100%
NET PROFIT FOR THE PERIOD	254	123	105%
EPS Rs.	2.1	1.0	
NET PROFIT BEFORE EXCEPTIONAL ITEM AND DISCONTINUING OPERATION			
	257	132	95%
Loss from discontinuing operation	-	8	-100%
Exceptional item, net of taxes	(4)	-	
NET PROFIT FOR THE PERIOD	254	123	105%
<i># Licensing Income</i>	8	8	
<i>* Gross Research & Development expenses</i>	136	139	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q4' FY 21	Q3' FY 21	Variance %
INCOME			
Generics	578	561	3%
Biosimilars	664	769	-14%
Novel Biologics	-	-	-
Research services	659	585	13%
Inter-segment	(61)	(63)	-3%
Revenue from operations #	1,839	1,851	-1%
Other income	205	28	636%
TOTAL REVENUE	2,044	1,879	9%
EXPENDITURE			
Material & Power costs	644	632	2%
Staff costs	414	411	1%
Research & Development expenses*	127	171	-26%
Other expenses	218	239	-9%
Manufacturing, staff & other expenses	1,403	1,452	-3%
EBITDA	641	427	50%
Interest & Finance charges	34	5	606%
Depreciation & Amortisation	184	186	-1%
Share of loss / (profit) in JV / Associate, net	70	-	100%
PBT BEFORE EXCEPTIONAL ITEM	354	236	50%
Exceptional item, Net	13	-	100%
PBT FROM CONTINUING OPERATIONS	366	236	55%
Taxes	60	49	22%
Taxes on exceptional item	10	-	100%
NET PROFIT BEFORE MINORITY INTEREST	297	187	58%
Minority interest	36	18	102%
Minority interest on exceptional item	7	-	100%
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	254	169	50%
LOSS FROM DISCONTINUING OPERATION	0	1	-63%
NET PROFIT FOR THE PERIOD	253	169	50%
EPS Rs.	2.1	1.4	
NET PROFIT BEFORE EXCEPTIONAL ITEM AND DISCONTINUING OPERATION			
	257	169	52%
Loss from discontinuing operation	0	1	-63%
Exceptional item, net of taxes	(4)	-	
NET PROFIT FOR THE PERIOD	253	169	50%
<i># Licensing Income</i>	8	11	
<i>* Gross Research & Development expenses</i>	136	183	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	FY 2021	FY 2020	Variance %
<u>INCOME</u>			
Generics	2,336	2,207	6%
Biosimilars	2,800	2,315	21%
Novel Biologics	-	-	-
Research services	2,184	2,012	9%
Inter-segment	(215)	(234)	-8%
Revenue from operations #	7,106	6,301	13%
Other income	255	161	58%
TOTAL REVENUE	7,360	6,462	14%
<u>EXPENDITURE</u>			
Material & Power costs	2,479	2,236	11%
Staff costs	1,566	1,328	18%
Research & Development expenses*	553	439	26%
Other expenses	856	694	23%
Manufacturing, staff & other expenses	5,453	4,697	16%
EBITDA	1,907	1,765	8%
Interest & Finance charges	58	65	-11%
Depreciation & Amortisation	715	552	30%
Share of loss / (profit) in JV / Associate, net	70	-	100%
PBT BEFORE EXCEPTIONAL ITEM	1,065	1,147	-7%
Exceptional item, Net	13	68	-81%
PBT FROM CONTINUING OPERATIONS	1,077	1,215	-11%
Taxes	212	250	-15%
Taxes on exceptional item	10	66	-85%
NET PROFIT BEFORE MINORITY INTEREST	856	900	-5%
Minority interest	99	109	-9%
Minority interest on exceptional item	7	14	-150%
NET PROFIT FOR THE PERIOD FROM CONTINUING OPERATIONS	750	777	-3%
LOSS FROM DISCONTINUING OPERATION	10	29	-66%
NET PROFIT FOR THE PERIOD	740	748	-1%
EPS Rs.	6.2	6.2	
NET PROFIT BEFORE DISCONTINUING OPERATION			
	754	789	-4%
Loss from discontinuing operation	10	29	-66%
Exceptional item, net of taxes	(4)	(12)	-68%
NET PROFIT FOR THE PERIOD	740	748	-1%
<i># Licensing Income</i>	40	31	
<i>* Gross Research & Development expenses</i>	627	527	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

Particulars	(Rs Crores)		
	March 31, 2021	March 31, 2020	Variance
ASSETS			
Non-current assets			
(a) Property, plant and equipment	5,557	5,393	164
(b) Capital work-in-progress	2,258	1,577	677
(c) Right-of-use assets	153	128	25
(d) Goodwill	26	26	-
(e) Other intangible assets	627	423	204
(f) Intangible assets under development	547	620	(73)
(g) Investment in associates and a joint venture	180	14	165
(h) Financial assets			
Investments	564	94	469
Derivative assets	66	26	40
Other financial assets	201	56	145
(i) Income tax asset, net	265	242	23
(j) Deferred tax asset, net	308	368	(60)
(k) Other non-current assets	176	151	24
Non-current assets	10,923	9,119	1,803
Current assets			
(a) Inventories	1,867	1,436	431
(b) Financial assets			
Investments	1,209	858	351
Trade receivables	1,218	1,224	(6)
Cash and cash equivalents	953	910	43
Other bank balances	1,062	89	974
Derivative assets	83	19	64
Other financial assets	793	450	343
(c) Other current assets	364	340	24
(c) Assets held for sale	52	-	52
Current assets	7,600	5,325	2,275
TOTAL - ASSETS	18,523	14,444	4,079
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	600	600	-
(b) Other equity	7,027	6,106	921
Equity attributable to owners of the Company	7,627	6,706	921
Non-controlling interests	881	677	203
Total Equity	8,508	7,383	1,125
Non-current liabilities			
(a) Financial liabilities			
Borrowings	2,962	1,222	1,739
Lease liabilities	114	83	31
Derivative liabilities	62	146	(84)
Other financial liabilities	1,503	536	967
(b) Provisions	106	86	20
(c) Deferred tax liability, net	32	30	3
(d) Other non-current liabilities	1,025	949	76
Non-current liabilities	5,805	3,053	2,752
Current liabilities			
(a) Financial liabilities			
Borrowings	594	668	(73)
Lease liabilities	8	7	2
Trade payables	1,514	1,325	189
Derivative liabilities	26	72	(46)
Other financial liabilities	1,184	1,208	(24)
(b) Provisions	109	103	6
(c) Current tax liabilities, net	152	128	25
(d) Other current liabilities	581	498	83
(e) Liabilities directly associated with assets held for sale	40	-	40
Current liabilities	4,210	4,008	202
TOTAL - EQUITY AND LIABILITIES	18,523	14,444	4,079